4.7 Article

Deformable double-shelled hollow mesoporous organosilica nanocapsules: A multi-interfacial etching strategy

Journal

CHINESE CHEMICAL LETTERS
Volume 32, Issue 3, Pages 1101-1105

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cclet.2020.08.023

Keywords

Hollow structure; Mesoporous; Double-shelled; Organosilica; Anticancer

Funding

  1. National Key Research and Development Program of China [2017YFA0205301, 2017YFA0205302]
  2. Key Research and Development Program of Jiangsu [BE2018732]
  3. National Natural Science Foundation of China [81971675, 21603106]
  4. Natural Science Foundation of Jiangsu Province [BK20160017]
  5. State Key Laboratory of Analytical Chemistry for Life Science [5431ZZXM1717]

Ask authors/readers for more resources

Deformable double-shelled hollow mesoporous organosilica nanocapsules (DDHMONs) with excellent biocompatibility and high drug loading capacity were successfully synthesized in this study. They can efficiently deliver anticancer drugs into cancer cells, demonstrating potential applications in nanomedicine as anticancer agents.
Multishelled hollow structures have drawn increasing interest because of their peculiar compartmentation environments and physicochemical properties. In this work, deformable double-shelled hollow mesoporous organosilica nanocapsules (DDHMONs) were successfully synthesized by a multi-interfacial etching strategy. The obtained DDHMONs have a double-shelled structure with aninorganic-organic hybrid framework, a uniform outer layer (similar to 320 nm) and inner layer (similar to 180 nm), ordered mesochannels (similar to 2.21 nm), and a large specific surface area (similar to 1233 m(2)/g). In vitro toxicity tests show that the DDHMONs have excellent biocompatibility when coincubated with human breast cancer cells. In addition, the anticancer substance doxorubicin (DOX) can be highly loaded in DDHMONs (similar to 335 mg/mg). The results from flow cytometry together with confocal laser scanning microscopy show that DOX can be efficiently delivered into MCF-7 cells by DDHMONs, thus improving chemotherapeutic efficiency and demonstrating that DDHMONs have potential nanomedicine applications as anticancer agents. (C) 2020 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available